Substituted Dipiperidine CCR2 Antagonists for Inflammatory Disease
Solution Overview
Problem
There is a need for small molecule CCR2 antagonists to prevent, treat, or ameliorate inflammatory syndromes, disorders, or diseases resulting from MCP-1 induced monocyte and lymphocyte migration to a site of inflammation, as current treatments have limitations in effectively addressing these conditions.
Innovation Solution
Substituted dipiperidine compounds, specifically piperidyl acrylamide derivatives, are developed as CCR2 antagonists that inhibit the interaction between MCP-1 and CCR2, thereby reducing inflammatory responses by administering a therapeutically effective amount of these compounds to a subject in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule CCR2 antagonists are developed to treat inflammatory conditions, then therapeutic effectiveness is improved, but compound complexity and development difficulty increase
Solution Approach 1:
The patent divides the CCR2 antagonist molecule into distinct functional segments: a piperidine core structure (providing basic pharmacological activity), heteroaryl substituents (enhancing binding affinity), and cyclohexanol moieties (modulating pharmacokinetic properties). This segmentation allows independent optimization of each component to achieve therapeutic effectiveness while managing overall molecular complexity.
Solution Approach 2:
The patent systematically varies key molecular parameters including substituent types on the piperidine ring, heteroaryl group identities, and stereochemical configurations to optimize the balance between binding affinity and pharmacokinetic properties. By changing these parameters across a series of compounds, the invention identifies optimal structures that achieve therapeutic effectiveness without excessive complexity.
2Object-affected harmful factors
If CCR2 antagonists are used to inhibit MCP-1 binding, then inflammatory response is reduced, but potential side effects and safety concerns increase
Solution Approach 1:
The patent introduces heteroaryl substituents at specific positions on the piperidine ring to create local regions of high binding affinity for CCR2, while other regions of the molecule are designed to minimize non-specific interactions. This local differentiation allows selective inhibition of the harmful inflammatory pathway while reducing generation of harmful side effects through targeted binding.
Solution Approach 2:
The cyclohexanol moieties act as intermediary structures that mediate between the piperidine core and the heteroaryl groups, providing steric bulk and hydrophobic interactions that enhance selective binding to CCR2. This intermediary structure allows the molecule to inhibit the harmful MCP-1/CCR2 pathway while maintaining safety by avoiding off-target effects.
3Reliability
If multiple substituents are added to enhance binding affinity, then CCR2 antagonism is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs pre-formed heteroaryl-piperidine building blocks that can be synthesized in advance through established methods, reducing the complexity of final assembly. By preparing key intermediates and modular units beforehand, the manufacturing process for the full CCR2 antagonists becomes more straightforward, maintaining high binding affinity while simplifying production.
Solution Approach 2:
The molecular structure exhibits a nested arrangement where heteroaryl groups are attached to the piperidine core, which itself contains the cyclohexanol moiety. This nested structural organization allows for systematic synthesis where inner components are assembled first, then outer substituents are added in subsequent steps, reducing overall manufacturing complexity while maintaining enhanced binding affinity through the nested functional groups.
Data Source
Figure 1
Figure 2
AI summary
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).